Cytoreductive treatment patterns among US veterans with polycythemia vera

BMC Cancer

Table 3 PV Treatment Patterns and Concomitant Medications During the Follow-Up Period

Treatment, n (%)	Patients With PV (N = 7718)
PV-related treatment^a
Pharmacologic cytoreductive treatment^b	1787 (23.2)
Hydroxyurea	1550 (20.1)
Anagrelide	206 (2.7)
Radiophosphorus	132 (1.7)
Interferon or PEGylated interferon	90 (1.2)
Busulfan	15 (0.2)
Phlebotomy^c	2531 (32.8)
Pharmacologic cytoreductive treatment and phlebotomy	688 (8.9)
No cytoreductive treatment or phlebotomy	4088 (53.0)
Aspirin^d	1815 (23.5)
Antiplatelet agents, not including aspirin	1511 (19.6)
Common concomitant medications
Antihypertensive agents	6671 (86.4)
ACE inhibitors	4226 (54.8)
Antilipid/anticholesterol agents	4882 (63.3)
Antidiabetic agents	2163 (28.0)
Anticoagulants	1313 (17.0)
Inotropic agents	580 (7.5)
Antiarrhythmic agents	362 (4.7)

ACE angiotensin-converting enzyme, PV polycythemia vera
^aRuxolitinib received approval from the US Food and Drug Administration for patients with PV who have had an inadequate response to or are intolerant of hydroxyurea after the end of the study period
^bPatients receiving pharmacologic cytoreductive treatment may have also received phlebotomy
^cPatients receiving phlebotomy may have also received pharmacologic cytoreductive treatment
^dIncludes both prescribed and over-the-counter aspirin and may underrepresent actual aspirin use

ISSN: 1471-2407